A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies

Exclusion Criteria

• •Subject is pregnant, lactating, or is planning to become pregnant during the study.
• •Subject has used any ectoparasiticide within the three weeks prior to study start.
• •Subject has signs of systemic infection or is receiving systemic therapy for an infectious disease.
• •Subject has severe cutaneous bacterial or fungal infections requiring therapy or heavily crusted lesions consistent with Norwegian scabies.
• •Subject is currently enrolled in an investigational drug or device study or has used an investigational drug or device within 30 days prior to study start.
• •Subject whose close personal contacts will not comply with standard of care for fomite management.